LIFE SCIENCE TREND ANALYSIS

NETHERLANDS | 2025





hollandbio



ABOUT US



The following statistical information has been obtained from **Biotechgate**, a global, comprehensive life science database encompassing the biotechnology, pharmaceutical and medical device industries.

www.biotechgate.com



The Dutch Life Sciences Database is a part of the global Biotechgate and is brought to you in partnership with **hollandbio**.

www.dutchlifescience.com



Biotechgate is owned and operated by **Venture Valuation AG**, a Zurich based company specializing in independent assessment and valuation of technology-driven companies in high growth industries, such as the life sciences (biotech, pharma, medtech), ICT, high-tech, nanotech, cleantech and renewable energy.

www.venturevaluation.com

OUR PARTNER

hollandbio

Hollandbio connects, supports, and represents over 280 medical, agro-food, and industrial biotech companies. Their members are active in all phases of research and development and include all company sizes: start-ups, SMEs, listed companies and multinationals.


Together, they strive for a society taking full advantage of the power of biotechnology in health, food and sustainability.


Explore the hollandbio life Science Database run by Biotechgate, which shows the Netherland's vibrant, dense biotechnology cluster of over 2000 life sciences companies and research organizations, all within a 120-mile radius.

OVERVIEW OF THE LIFE SCIENCE INDUSTRY

NUMBER OF COMPANIES BY SECTOR










OVERVIEW OF BIOTECH COMPANIES

NUMBER OF COMPANIES BY SECTOR




• BIOTECH • THERAPEUTICS
184

BIOTECH COMPANIES 542 • BIOTECH • R&D SERVICES
216

• BIOTECH • OTHER
142

BIOTECH - THERAPEUTICS & DIAGNOSTICS COMPANIES BY KEY ACTIVITIES


AS PERCENTAGE OF TOTAL NUMBER OF BIOTECH - THERAPEUTICS COMPANIES






BIOTECH - OTHER COMPANIES BY KEY ACTIVITIES

AS PERCENTAGE OF TOTAL NUMBER OF BIOTECH - OTHER COMPANIES











BIOTECH ASSETS IN CLINICAL DEVELOPMENT

BY INDICATION AND DEVELOPMENT PHASE

BREAKDOWN BY INDICATION



BREAKDOWN BY DEVELOPMENT PHASE




Both graphs contain the number of assets of Biotech – Therapeutics and Diagnostics companies (excl. Pharma or Biotech – Others or Biotech R&D Services companies). Products in Discovery and Lead Optimization Phase are merged into Preclinical; Development Phase I/II trials are merged into Phase II and Phase II/III trials are merged into Phase III category. Information displayed in the chart may alter as new information is received continuously.

Number of Assets




ASSETS AVAILABLE FOR OUT-LICENSING

NUMBER OF ASSETS



OVERVIEW OF OWNERSHIP

PERCENTAGE OF TOTAL NUMBER OF COMPANIES BY OWNERSHIP AND SECTOR








COMPANY FOUNDATION TIMELINE

NUMBER OF LIFE SCIENCE COMPANIES FOUNDED BY YEAR | 2014-2023



The graph contains the number of privately owned or publicly listed (no subsidiaries) life science companies founded by year including Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. **Companies founded in 2024 were excluded** since newly founded companies often remain under the radar until their first financing round. The information displayed in the chart may alter as new information is received continuously.




VENTURE FINANCING OF LIFE SCIENCE COMPANIES

PRIVATE EQUITY ROUNDS | 2023-2024

LIFE SCIENCE COMPANIES




BIOTECH COMPANIES






BIOTECH VENTURE FINANCING

PRIVATE EQUITY ROUNDS - 5 YEAR REPORT



BIOTECH IPOs

DUTCH BIOTECH COMPANIES THAT WENT PUBLIC WORLDWIDE | 2015-2024



MAJOR BIOTECH VENTURE FINANCING ROUNDS (2024)

TOP 5 DUTCH PRIVATE EQUITY FINANCING ROUNDS | 2024

Company		Sector	Type of Round	USD M
Citryll BV	Citryll	Biotech – Therapeutics	Series B	\$89.39
iOnctura BV	ionctura	Biotech – Therapeutics	Series B	\$87.03
Cradle Bio B.V.	ور تروی	Biotech – R&D	Series B	\$73.00
VICO Therapeutics B.V.	VICO Therapeutics	Biotech – Therapeutics	Series B	\$59.15
BioBTX	BioBTX	Biotech – Other	Other/Unknown	\$45.69

MAJOR BIOTECH AND PHARMA M&A DEALS (2024)

TOP 5 M&A DEALS | 2024

Acquired	entity	Buyer		Phase of lead asset (of acquired entity)	USD M
Calypso Biotech BV	© Calypso biotech	Novartis AG	U NOVARTIS	Phase I	\$425
ZoBio BV	ZoBio	Oncodesign Services	©ncodesign services	N/A	N/A
Cyclomics Bv		GEDi Cube BV	∘¹°∏∏i₀ GEDi Cube	N/A	N/A
GEDi Cube BV	oti∏∏i.o GEDi Cube	Renovaro Inc.	RENOVARO LIVE LONGER	N/A	N/A
NeuroReality	NEUROREALITY	XRHealth	XR Health	N/A	N/A

BENCHMARK REPORT

NETHERLANDS | FRANCE | GERMANY | UNITED KINGDOM | DENMARK | SWITZERLAND | USA









OVERVIEW OF LIFE SCIENCE COMPANIES

LIFE SCIENCE AND BIOTECH COMPANIES BY COUNTRY AND SECTOR




OVERVIEW OF LIFE SCIENCE COMPANIES

LIFE SCIENCE COMPANIES BY COUNTRY AND SECTOR



OVERVIEW OF BIOTECH COMPANIES


BIOTECH COMPANIES BY COUNTRY AND SECTOR





BIOTECH ASSETS IN CLINICAL DEVELOPMENT

BREAKDOWN BY TOP THREE INDICATIONS OF NETHERLANDS








THERAPEUTICS BY DEVELOPMENT PHASE

PRECLINICAL AND PHASE I








COMPANY FOUNDATION TIMELINE


RATE OF LIFE SCIENCE COMPANIES FOUNDED BY YEAR PER MILLION RESIDENTS | 2014-2023




VENTURE FINANCING OF LIFE SCIENCE COMPANIES


PRIVATE EQUITY ROUNDS OF LIFE SCIENCE COMPANIES (EUROPE AND USA) | 2023-2024

LIFE SCIENCE COMPANIES



BIOTECH COMPANIES










VENTURE FINANCING OF LIFE SCIENCE COMPANIES

PRIVATE EQUITY ROUNDS OF LIFE SCIENCE COMPANIES | 2023-2024

Life Science companies include Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech - Others, Pharma, Medical Technology and Digital Health companies. Financing data only includes private equity rounds (excl. private placements in public companies). Data may alter as new information is continuously

received and/or new tranches to existing financing rounds are added. The graph shows the benchmark countries excl. the United States.








VENTURE FINANCING OF BIOTECH COMPANIES

PRIVATE EQUITY ROUNDS OF BIOTECH COMPANIES | 2023-2024







MAJOR BIOTECH VENTURE FINANCING ROUNDS (2024)

TOP PRIVATE EQUITY FINANCING ROUNDS | 2024

Company	Type of Round	USD M	Country
Alentis Therapeutics AG	Series D	\$181.40	Switzerland
CatalYm GmbH	Series D	\$150.00	Germany
Noema Pharma AG	Series B	\$147.38	Switzerland
Ottimo Pharma Ltd	Series A	\$140.00	United Kingdom
Tubulis GmbH	Series B	\$138.80	Germany
Adcendo ApS	Series B	\$135.00	Denmark
Pheon Therapeutics Ltd.	Series B	\$120.00	United Kingdom
Purespring Therapeutics	Series B	\$105.00	United Kingdom
Vicebio	Series B	\$100.00	United Kingdom
F2G Ltd	Series A	\$100.00	United Kingdom

ABOUT BIOTECHGATE



Biotechgate is a leading **business development and licensing database** for the entire life science industry, offering a wealth of information on over 65,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 44,000 **licensing deals** and a **clinical trials database** containing over 950,000 records from registries around the world.

To request a free demo or to learn more about the different subscription options, please visit Biotechgate.

TERMS OF USE

The Life Sciences Trend Analysis is based on data entered in the Biotechgate Database available at www.biotechgate.com. The statistics and graphs in this presentation are based on figures and information entered in this database and we do not guarantee any accuracy hereof.

The use of the figures and graphs provided in this report is free of charge for any presentations as long as www.biotechgate.com is clearly cited as the source. For all other uses please contact us for terms and conditions.



BIOTECHGATE

c/o Venture Valuation VV AG

Kasernenstrasse 11

8004 Zurich

SWITZERLAND



+41 (43) 321 86 60



www.venturevaluation.com